Sign up
Pharma Capital

LBT Innovations raises capital and generates sales leads in the US

LBT Innovations Limited (ASX:LBT) chief executive officer Brent Barnes updates Proactive Investors on developments to forge ahead with product sales of its unique APAS Independence technology. 
 
The ground-breaking medical technology company has also raised $5 million on the back of FDA clearance, which will enable the execution of commercialisation plans.
 
Barnes will attend this week's American Society of Microbiology Microbe meeting in San Francisco to further showcase the APAS Independence to the US and global markets.
 

View full LBT profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.